Table 1 Urine output, free water clearance (CH2O), urinary AQP2 excretion per minute (u-AQP2), urinary sodium excretion (u-Na), and urinary potassium excretion (u-K) during 24-h urine collection in a randomised, placebo-controlled, double-blind, crossover study of 18 ADPKD patients
From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study
| |
Before each examination day
|
p (paired t-test)
|
|---|
|
Placebo
|
Tolvaptan 60 mg
|
|---|
|
Urine Output (ml/24 h)
|
2504 ± 518
|
2446 ± 615
|
0.57
|
|
CH2O (ml/min)
|
−0.22 ± 0.55
|
−0.19 ± 0.57
|
0.72
|
|
u-AQP2 (ng/min)
|
1.10 ± 0.26
|
1.09 ± 0.28
|
0.88
|
|
u-Na (mmol/24 h)
|
117 ± 34
|
111 ± 28
|
0.46
|
|
u-K (mmol/24 h)
|
66 ± 17
|
65 ± 18
|
0.77
|
- Values are means with ± SD. Paired t-test was used for comparison between groups
